Niagen Bioscience (NAGE) Financials

$4.82 -0.11 (-2.23%)

Closing price 04:00 PM Eastern

Extended Trading

$4.84 +0.02 (+0.39%)

As of 06:18 PM Eastern

Annual Income Statements for Niagen Bioscience

This table shows Niagen Bioscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/3/2015	1/2/2016	12/31/2016	12/30/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-5.39	-2.77	-2.93	-11	-33	-32	-20	-27	-17	-4.94	8.55
Consolidated Net Income / (Loss)	-5.39	-2.77	-2.93	-11	-33	-32	-20	-27	-17	-4.94	8.55
Net Income / (Loss) Continuing Operations	-5.39	-2.64	-3.55	-17	-33	-32	-20	-27	-17	-4.94	8.55
Total Pre-Tax Income	-5.39	-2.63	-3.55	-17	-33	-32	-20	-27	-19	-4.94	8.86
Total Operating Income	-5.23	-2.07	-2.91	-16	-33	-31	-20	-27	-19	-5.60	7.73
Total Gross Profit	5.33	7.53	10	10	16	26	35	41	43	51	62
Total Revenue	15	18	22	21	32	46	59	67	72	84	100
Operating Revenue	15	18	22	21	32	46	59	67	72	84	100
Total Cost of Revenue	9.99	10	11	11	16	21	24	26	29	33	38
Operating Cost of Revenue	9.99	10	11	11	16	21	24	26	29	33	38
Total Operating Expenses	11	9.60	13	27	49	57	55	69	61	56	54
Selling, General & Admin Expense	7.86	7.20	9.21	18	27	34	31	36	28	25	18
Marketing Expense	2.14	1.51	1.56	4.46	17	18	21	28	28	26	29
Research & Development Expense	0.51	0.89	2.52	4.01	5.48	4.42	3.42	3.83	4.83	4.96	6.02
Total Other Income / (Expense), net	-0.16	-0.57	-0.65	-0.15	-0.14	-0.85	-0.07	-0.06	0.00	0.66	1.13
Interest & Investment Income	0.00	-	-	-	-	-	-	-	-	0.66	1.13
Income Tax Expense	0.00	-0.00	0.00	-	-	-	-	-	-	0.00	0.31
Basic Earnings per Share	($0.15)	($0.08)	($0.08)	($0.26)	($0.61)	($0.56)	($0.33)	($0.40)	($0.24)	($0.07)	$0.11
Weighted Average Basic Shares Outstanding	35.49M	35.88M	37.29M	44.60M	55.01M	57.06M	61.07M	67.19M	69.73M	74.99M	75.93M
Diluted Earnings per Share	($0.15)	($0.08)	($0.08)	($0.26)	($0.61)	($0.56)	($0.33)	($0.40)	($0.24)	($0.07)	$0.11
Weighted Average Diluted Shares Outstanding	35.49M	35.88M	37.29M	44.60M	55.01M	57.06M	61.07M	67.19M	69.73M	74.99M	78.13M
Weighted Average Basic & Diluted Shares Outstanding	35.49M	35.88M	37.29M	44.60M	55.01M	57.06M	61.07M	68.31M	74.84M	75.31M	77.75M

This table shows Niagen Bioscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-0.99	-1.42	-1.90	-2.19	-0.96	0.11	-0.49	-0.02	1.88	7.18	5.06
Consolidated Net Income / (Loss)	-0.99	-1.42	-1.90	-2.19	-0.96	0.11	-0.49	-0.02	1.88	7.18	5.06
Net Income / (Loss) Continuing Operations	-0.99	-1.42	-1.90	-2.19	-0.96	0.11	-0.49	-0.02	1.88	7.18	5.06
Total Pre-Tax Income	-3.07	-1.42	-1.90	-2.19	-0.96	0.11	-0.49	-0.02	1.88	7.48	5.23
Total Operating Income	-3.07	-1.44	-1.97	-2.32	-1.15	-0.17	-0.73	-0.26	1.60	7.11	4.77
Total Gross Profit	10	12	14	12	12	13	13	14	16	18	19
Total Revenue	17	21	23	20	19	21	22	23	26	29	30
Operating Revenue	17	21	23	20	19	21	22	23	26	29	30
Total Cost of Revenue	6.86	8.98	9.04	7.97	7.53	8.26	8.70	9.05	9.34	11	11
Operating Cost of Revenue	6.86	8.98	9.04	7.97	7.53	8.26	8.70	9.05	9.34	11	11
Total Operating Expenses	13	13	15	15	13	13	14	14	15	11	15
Selling, General & Admin Expense	6.18	5.99	6.42	7.30	5.84	5.43	5.35	5.66	6.30	1.06	5.18
Marketing Expense	5.87	6.19	7.87	6.01	6.04	6.52	6.74	6.97	7.04	8.72	8.12
Research & Development Expense	1.22	1.28	1.19	1.37	1.24	1.16	2.10	1.32	1.29	1.32	1.26
Total Other Income / (Expense), net	-0.01	0.03	0.07	0.13	0.19	0.28	0.24	0.24	0.28	0.37	0.46
Interest & Investment Income	-	-	-	0.13	0.19	-	0.24	0.24	0.28	-	0.46
Income Tax Expense	-	-	-	-	-	-	0.00	-	-	-	0.17
Basic Earnings per Share	($0.01)	($0.03)	($0.03)	($0.03)	($0.01)	-	($0.01)	$0.00	$0.02	$0.10	$0.07
Weighted Average Basic Shares Outstanding	68.35M	69.73M	74.80M	74.97M	75.05M	74.99M	75.23M	75.56M	75.97M	75.93M	77.81M
Diluted Earnings per Share	($0.01)	($0.03)	($0.03)	($0.03)	($0.01)	-	($0.01)	$0.00	$0.02	$0.10	$0.06
Weighted Average Diluted Shares Outstanding	68.35M	69.73M	74.80M	74.97M	75.05M	74.99M	75.23M	75.56M	77.77M	78.13M	83.23M
Weighted Average Basic & Diluted Shares Outstanding	74.47M	74.84M	74.97M	75.03M	75.12M	75.31M	75.54M	75.93M	76.38M	77.75M	78.77M

This table details how cash moves in and out of Niagen Bioscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/3/2015	1/2/2016	12/31/2016	12/30/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	1.70	1.58	-3.91	44	-23	-3.80	-2.12	12	-7.78	6.88	17
Net Cash From Operating Activities	-2.58	-2.11	-2.94	-9.80	-21	-20	-11	-24	-15	7.12	12
Net Cash From Continuing Operating Activities	-2.68	8.68	5.08	-4.51	-18	-12	-11	-24	-15	7.12	12
Net Income / (Loss) Continuing Operations	-5.39	-2.77	-2.93	-11	-33	-32	-20	-27	-17	-4.94	8.55
Consolidated Net Income / (Loss)	-5.39	-2.77	-2.93	-11	-33	-32	-20	-27	-17	-4.94	8.55
Depreciation Expense	0.22	0.29	0.33	0.51	0.61	0.76	0.87	0.89	0.87	0.87	0.66
Amortization Expense	0.04	0.05	0.09	0.21	0.24	1.61	0.64	0.74	1.02	0.16	0.15
Non-Cash Adjustments To Reconcile Net Income	3.06	2.54	2.34	-1.19	6.27	8.91	6.87	6.35	5.88	6.47	-1.00
Changes in Operating Assets and Liabilities, net	-0.51	-2.21	-2.77	2.04	5.29	0.43	0.94	-5.01	-6.32	4.56	3.75
Net Cash From Investing Activities	1.59	-0.65	-1.72	4.60	-1.78	-0.25	-0.17	-0.41	-0.33	-0.14	-0.14
Net Cash From Continuing Investing Activities	1.59	-0.65	-1.72	4.60	-1.78	0.15	-0.17	-0.41	-0.33	-0.14	-0.14
Other Investing Activities, net	0.00	-	-	-	0.00	0.49	-0.02	-	0.00	0.01	-0.14
Net Cash From Financing Activities	2.69	4.34	0.75	49	-0.09	17	8.65	36	7.65	-0.09	5.37
Net Cash From Continuing Financing Activities	2.69	4.34	0.75	49	-0.09	17	8.65	36	7.65	-0.09	5.37
Repayment of Debt	-0.27	-0.23	-5.40	-0.68	-0.22	-0.39	-0.32	-0.11	-0.09	-0.09	-0.06
Other Financing Activities, net	0.47	2.59	0.44	3.04	0.53	11	4.12	9.46	-	0.00	5.43
Cash Interest Paid	0.07	0.43	0.26	0.06	0.04	0.03	0.01	0.00	0.00	0.00	0.00

This table details how cash moves in and out of Niagen Bioscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-3.81	7.18	2.70	3.27	0.37	0.55	0.24	0.32	4.51	12	11
Net Cash From Operating Activities	-3.74	-0.33	2.79	3.28	0.40	0.65	0.30	-0.26	3.50	8.58	7.88
Net Cash From Continuing Operating Activities	-3.74	-0.33	2.79	3.28	0.40	0.65	0.30	-0.26	3.50	8.58	7.88
Net Income / (Loss) Continuing Operations	-0.99	-1.42	-1.90	-2.19	-0.96	0.11	-0.49	-0.02	1.88	7.18	5.06
Consolidated Net Income / (Loss)	-0.99	-1.42	-1.90	-2.19	-0.96	0.11	-0.49	-0.02	1.88	7.18	5.06
Depreciation Expense	0.24	0.22	0.23	0.23	0.23	0.18	0.18	0.17	0.16	0.15	0.16
Amortization Expense	0.21	0.23	0.21	0.21	0.22	-0.48	0.04	0.20	0.20	-0.46	0.04
Non-Cash Adjustments To Reconcile Net Income	1.26	1.37	1.61	1.78	1.33	1.75	1.21	1.22	0.75	-4.01	-0.06
Changes in Operating Assets and Liabilities, net	-4.46	-0.74	2.64	3.25	-0.42	-0.91	-0.64	-1.84	0.50	5.73	2.68
Net Cash From Investing Activities	-0.05	-0.17	-0.09	-0.01	-0.03	-0.02	-0.04	-0.01	-0.02	-0.07	-0.03
Net Cash From Continuing Investing Activities	-0.05	-0.17	-0.09	-0.01	-0.03	-0.02	-0.04	-0.01	-0.02	-0.07	-0.03
Purchase of Property, Plant & Equipment	-0.05	-0.17	-0.09	-0.01	-0.03	-0.02	-0.04	-0.01	-0.04	-	-0.03
Net Cash From Financing Activities	-0.02	7.68	-0.00	-0.01	-0.00	-0.08	-0.01	0.60	1.04	3.75	3.11
Net Cash From Continuing Financing Activities	-0.02	7.68	-0.00	-0.01	-0.00	-0.08	-0.01	0.60	1.04	3.75	3.11
Repayment of Debt	-0.02	-0.07	-0.00	-0.01	-0.00	-0.08	-0.01	-0.00	-0.00	-0.04	-0.01
Other Financing Activities, net	-	-	-	-	-	-	0.00	-	1.04	3.79	3.11

This table presents Niagen Bioscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/3/2015	1/2/2016	12/31/2016	12/30/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	12	19	20	63	42	40	38	58	54	55	68
Total Current Assets	9.90	17	16	57	37	34	32	49	47	50	64
Cash & Equivalents	3.96	5.55	1.64	45	23	19	17	-	20	27	45
Accounts Receivable	1.91	2.45	5.85	5.34	4.36	-	2.69	5.23	8.48	5.23	7.77
Inventories, net	3.73	8.17	7.91	5.80	8.25	12	12	14	15	15	9.19
Prepaid Expenses	0.29	0.37	0.31	0.66	0.58	1.00	1.15	1.86	2.97	2.45	2.48
Plant, Property, & Equipment, net	1.26	1.79	1.78	2.87	3.59	3.77	0.00	0.00	2.80	2.14	1.72
Total Noncurrent Assets	0.35	0.41	2.24	2.67	2.11	2.96	6.14	8.94	4.69	3.29	2.46
Intangible Assets	0.30	0.35	0.49	1.65	1.55	1.31	1.08	0.86	0.67	0.51	0.36
Other Noncurrent Operating Assets	0.06	0.06	0.38	1.02	0.57	1.65	1.85	5.08	4.02	2.78	2.10
Total Liabilities & Shareholders' Equity	12	19	20	63	42	40	38	58	54	55	68
Total Liabilities	7.52	13	9.78	8.89	15	20	22	26	25	27	22
Total Current Liabilities	4.98	9.59	8.87	8.09	14	15	16	18	18	21	18
Accounts Payable	3.45	6.22	5.98	3.72	9.55	9.63	9.45	10	9.68	10	8.53
Accrued Expenses	0.85	1.30	2.17	3.65	4.44	4.42	6.13	6.48	7.34	9.49	7.82
Current Deferred Revenue	0.07	0.04	0.08	0.11	-	-	0.28	-	0.16	0.20	0.61
Other Current Liabilities	-	-	-	-	0.17	0.85	0.62	0.55	0.70	0.70	0.99
Total Noncurrent Liabilities	2.54	3.89	0.91	0.80	0.61	4.74	5.46	8.50	7.52	5.89	4.24
Noncurrent Deferred Revenue	0.14	0.10	0.38	0.49	0.48	3.87	4.44	4.35	3.96	3.31	2.58
Other Noncurrent Operating Liabilities	-	-	-	-	0.14	0.87	1.00	4.15	3.56	2.58	1.66
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	4.00	5.27	9.97	54	27	20	16	32	29	28	46
Total Preferred & Common Equity	4.00	5.27	9.97	54	27	20	16	32	29	28	46
Total Common Equity	4.00	5.27	9.97	54	27	20	16	32	29	28	46
Common Stock	44	48	55	110	117	142	158	201	214	219	228
Retained Earnings	-40	-42	-45	-57	-90	-122	-142	-169	-185	-190	-182
Other Equity Adjustments	-	-	-	-	-	0.00	-0.00	-0.00	-0.00	-0.00	-0.00

This table presents Niagen Bioscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	47	46	54	53	53	54	54	57	81
Total Current Assets	39	38	47	46	47	49	49	52	76
Cash & Equivalents	-	13	23	26	27	28	28	32	56
Accounts Receivable	4.23	4.74	9.22	6.12	5.60	6.60	7.82	7.10	7.05
Inventories, net	16	16	12	12	13	12	12	11	11
Prepaid Expenses	1.46	4.26	2.30	1.89	2.18	2.31	2.09	2.10	2.37
Plant, Property, & Equipment, net	0.00	2.79	2.69	2.50	2.29	2.00	1.84	1.72	1.66
Total Noncurrent Assets	8.11	4.97	4.51	4.29	4.01	3.10	2.89	2.67	3.46
Intangible Assets	0.76	0.71	0.63	0.59	0.55	0.47	0.44	0.40	0.32
Other Noncurrent Operating Assets	4.45	4.26	3.88	3.70	3.46	2.63	2.46	2.27	3.14
Total Liabilities & Shareholders' Equity	47	46	54	53	53	54	54	57	81
Total Liabilities	26	25	26	26	26	25	23	22	26
Total Current Liabilities	18	17	18	19	19	19	18	18	21
Accounts Payable	10	9.12	8.95	10	9.20	7.90	8.11	6.90	11
Accrued Expenses	6.70	6.76	8.61	8.08	9.19	10	8.62	9.59	9.05
Current Deferred Revenue	-	-	0.15	0.17	0.19	0.23	0.16	0.18	0.21
Other Current Liabilities	0.01	0.69	0.71	0.79	0.86	0.86	0.99	1.02	0.95
Total Noncurrent Liabilities	8.11	7.92	7.33	6.96	6.73	5.68	5.45	4.45	5.16
Noncurrent Deferred Revenue	4.23	4.23	3.96	3.81	3.81	3.31	3.31	2.58	2.58
Other Noncurrent Operating Liabilities	3.88	3.69	3.37	3.15	2.93	2.37	2.14	1.88	2.58
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	21	21	28	27	27	29	31	34	55
Total Preferred & Common Equity	21	21	28	27	27	29	31	34	55
Total Common Equity	21	21	28	27	27	29	31	34	55
Common Stock	204	205	215	217	218	220	222	223	232
Retained Earnings	-183	-184	-187	-190	-191	-191	-191	-189	-177
Other Equity Adjustments	0.00	-	-	-	-	-0.00	-0.00	-0.01	-0.01

This table displays calculated financial ratios and metrics derived from Niagen Bioscience's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	1/3/2015	1/2/2016	12/31/2016	12/30/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	50.71%	16.79%	21.13%	-2.14%	48.85%	46.69%	28.01%	13.82%	6.82%	15.99%	19.18%
EBITDA Growth	-20.80%	65.10%	-43.22%	-530.06%	-106.85%	8.08%	38.41%	-38.74%	34.20%	72.70%	286.83%
EBIT Growth	-19.26%	60.51%	-40.61%	-463.71%	-102.95%	3.28%	38.24%	-36.36%	31.19%	69.94%	237.99%
NOPAT Growth	-19.26%	60.51%	-40.61%	-463.71%	-102.55%	5.64%	36.57%	-36.36%	31.19%	69.94%	290.34%
Net Income Growth	-21.92%	48.57%	-5.67%	-288.57%	-192.81%	3.51%	38.02%	-36.15%	39.03%	70.15%	273.15%
EPS Growth	-275.00%	46.67%	0.00%	-225.00%	-134.62%	8.20%	41.07%	-21.21%	40.00%	70.83%	257.14%
Operating Cash Flow Growth	33.94%	18.19%	-39.10%	-233.86%	-113.26%	2.24%	48.14%	-127.95%	37.52%	147.14%	70.14%
Free Cash Flow Firm Growth	-246.72%	13.85%	-15.13%	-182.35%	-48.39%	-0.79%	36.72%	-89.08%	21.79%	117.91%	125.01%
Invested Capital Growth	44.94%	87.61%	46.76%	15.88%	-49.03%	-64.20%	-115.49%	1,486.56%	134.64%	-86.26%	26.79%
Revenue Q/Q Growth	13.67%	-18.31%	6.54%	39.15%	5.12%	9.52%	4.14%	3.55%	4.70%	0.24%	8.65%
EBITDA Q/Q Growth	-8.32%	-1.91%	-187.04%	-60.80%	1.62%	-4.72%	13.31%	2.89%	19.04%	10.16%	338.85%
EBIT Q/Q Growth	-8.03%	-2.45%	-132.04%	-57.39%	1.40%	-4.78%	12.28%	2.75%	17.21%	18.56%	1,628.41%
NOPAT Q/Q Growth	-8.03%	-2.45%	-132.04%	-57.39%	1.60%	-2.02%	12.28%	2.75%	17.21%	18.56%	1,568.88%
Net Income Q/Q Growth	-10.30%	-7.75%	-32.61%	-141.94%	1.78%	-2.02%	12.15%	2.77%	19.11%	23.68%	475.76%
EPS Q/Q Growth	-200.00%	42.86%	-33.33%	-85.71%	4.69%	0.00%	13.16%	6.98%	14.29%	30.00%	1,000.00%
Operating Cash Flow Q/Q Growth	36.56%	-40.43%	26.24%	-67.71%	-7.01%	18.13%	5.63%	-25.87%	23.41%	15.91%	190.04%
Free Cash Flow Firm Q/Q Growth	23.59%	-13.64%	22.23%	-69.18%	0.13%	24.95%	-14.53%	-27.34%	16.65%	23.69%	823.65%
Invested Capital Q/Q Growth	-10.81%	1.82%	-23.31%	-13.01%	-17.79%	-82.56%	-106.31%	48.77%	3.94%	111.40%	-27.25%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	34.78%	42.13%	47.96%	49.42%	50.88%	55.67%	59.53%	61.51%	59.40%	60.76%	61.84%
EBITDA Margin	-32.48%	-9.70%	-11.47%	-73.87%	-102.66%	-64.33%	-30.95%	-37.73%	-23.24%	-5.47%	8.57%
Operating Margin	-34.16%	-11.55%	-13.41%	-77.25%	-105.12%	-67.62%	-33.50%	-40.14%	-25.85%	-6.70%	7.76%
EBIT Margin	-34.16%	-11.55%	-13.41%	-77.25%	-105.32%	-69.45%	-33.50%	-40.14%	-25.85%	-6.70%	7.76%
Profit (Net Income) Margin	-35.19%	-15.49%	-13.52%	-53.67%	-105.57%	-69.45%	-33.62%	-40.22%	-22.96%	-5.91%	8.58%
Tax Burden Percent	100.00%	105.24%	82.45%	68.83%	100.00%	100.00%	100.00%	100.00%	88.81%	100.00%	96.56%
Interest Burden Percent	103.00%	127.44%	122.25%	100.93%	100.24%	100.00%	100.36%	100.20%	99.98%	88.19%	114.61%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.44%
Return on Invested Capital (ROIC)	-154.48%	-35.85%	-31.32%	-137.50%	-343.68%	-707.34%	-2,014.17%	-1,164.43%	-222.16%	-83.73%	581.67%
ROIC Less NNEP Spread (ROIC-NNEP)	-84.35%	184.13%	47.79%	-137.86%	-313.76%	-657.92%	-1,980.21%	-1,128.00%	-207.77%	-79.46%	578.64%
Return on Net Nonoperating Assets (RNNOA)	42.97%	-23.92%	-7.09%	101.83%	261.43%	572.34%	1,906.09%	1,051.75%	167.39%	66.44%	-558.73%
Return on Equity (ROE)	-111.51%	-59.77%	-38.40%	-35.66%	-82.25%	-135.01%	-108.09%	-112.68%	-54.77%	-17.29%	22.94%
Cash Return on Invested Capital (CROIC)	-191.18%	-96.77%	-69.22%	-152.21%	-278.72%	-612.78%	0.00%	-647.44%	-302.63%	67.95%	558.04%
Operating Return on Assets (OROA)	-51.03%	-13.65%	-15.09%	-39.71%	-63.34%	-77.95%	-50.52%	-56.29%	-33.29%	-10.27%	12.54%
Return on Assets (ROA)	-52.56%	-18.31%	-15.21%	-27.59%	-63.49%	-77.95%	-50.70%	-56.40%	-29.56%	-9.06%	13.88%
Return on Common Equity (ROCE)	-111.51%	-59.77%	-38.40%	-35.66%	-82.25%	-135.01%	-108.09%	-112.68%	-54.77%	-17.29%	22.94%
Return on Equity Simple (ROE_SIMPLE)	-134.76%	-52.54%	-29.36%	-21.14%	-122.58%	-157.24%	-121.32%	-85.50%	-57.69%	-17.35%	18.55%
Net Operating Profit after Tax (NOPAT)	-3.66	-1.45	-2.03	-11	-23	-22	-14	-19	-13	-3.92	7.46
NOPAT Margin	-23.91%	-8.09%	-9.39%	-54.07%	-73.58%	-47.33%	-23.45%	-28.10%	-18.10%	-4.69%	7.49%
Net Nonoperating Expense Percent (NNEP)	-70.13%	-219.98%	-79.11%	0.36%	-29.91%	-49.42%	-33.97%	-36.43%	-14.39%	-4.27%	3.03%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	-13.77%	16.18%
Cost of Revenue to Revenue	65.22%	57.87%	52.04%	50.58%	49.12%	44.33%	40.47%	38.49%	40.60%	39.24%	38.16%
SG&A Expenses to Revenue	51.33%	40.26%	42.53%	86.73%	86.23%	74.38%	51.92%	53.94%	39.26%	29.89%	18.45%
R&D to Revenue	3.35%	4.99%	11.64%	18.90%	17.36%	9.55%	5.76%	5.68%	6.70%	5.93%	6.04%
Operating Expenses to Revenue	68.94%	53.68%	61.37%	126.66%	155.99%	123.28%	93.03%	101.65%	85.25%	67.46%	54.08%
Earnings before Interest and Taxes (EBIT)	-5.23	-2.07	-2.91	-16	-33	-32	-20	-27	-19	-5.60	7.73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-4.97	-1.74	-2.49	-16	-32	-30	-18	-25	-17	-4.57	8.54
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	39.31	30.41	12.58	5.26	6.95	12.56	18.06	8.05	4.36	3.78	8.79
Price to Tangible Book Value (P/TBV)	42.45	32.60	13.22	5.43	7.37	13.42	19.33	8.27	4.47	3.84	8.86
Price to Revenue (P/Rev)	10.26	8.97	5.79	13.36	5.99	5.55	5.01	3.79	1.74	1.29	4.07
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	47.39
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.11%
Enterprise Value to Invested Capital (EV/IC)	55.60	30.47	16.11	26.64	36.47	145.72	0.00	64.76	12.72	70.82	251.43
Enterprise Value to Revenue (EV/Rev)	10.19	8.97	5.74	11.25	5.27	5.14	4.72	3.37	1.45	0.96	3.62
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	42.22
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	46.67
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	48.33
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.26	29.78
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	25.18	50.38
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.69	1.05	0.06	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.60	0.72	0.03	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.51	-0.13	-0.15	-0.74	-0.83	-0.87	-0.96	-0.93	-0.81	-0.84	-0.97
Leverage Ratio	2.12	3.26	2.52	1.29	1.30	1.73	2.13	2.00	1.85	1.91	1.65
Compound Leverage Factor	2.19	4.16	3.09	1.30	1.30	1.73	2.14	2.00	1.85	1.68	1.89
Debt to Total Capital	40.94%	51.22%	5.67%	0.93%	0.00%	0.00%	0.12%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	5.49%	16.17%	2.42%	0.36%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	35.45%	35.05%	3.25%	0.57%	0.00%	0.00%	0.12%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	59.06%	48.78%	94.33%	99.07%	100.00%	100.00%	99.88%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.56	-3.19	-0.24	-0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.24	0.01	0.43	2.87	0.00	0.00	0.91	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.48	-2.18	-0.14	-0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.76	-3.83	-0.29	-0.04	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.33	0.01	0.52	3.92	0.00	0.00	1.20	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.66	-2.62	-0.17	-0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	8.08	5.02	5.52	18.28	3.34	2.60	3.27	2.05	-1.01	-0.60	9.87
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.99	1.73	1.77	7.07	2.53	2.23	1.96	2.78	2.61	2.40	3.57
Quick Ratio	1.18	0.83	0.85	6.27	1.87	1.25	1.18	0.30	1.62	1.58	2.92
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-4.53	-3.90	-4.49	-13	-19	-19	-12	-23	-18	3.18	7.16
Operating Cash Flow to CapEx	-2,096.26%	-401.94%	-195.13%	0.00%	-1,582.74%	-2,750.87%	-8,548.39%	-5,907.82%	-4,520.36%	4,808.78%	0.00%
Free Cash Flow to Firm to Interest Expense	-28.53	-6.89	-6.95	-82.95	-238.37	0.00	-169.18	-412.95	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-16.24	-3.72	-4.54	-64.08	-264.66	0.00	-149.30	-439.33	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-17.02	-4.65	-6.87	-32.80	-281.38	0.00	-151.04	-446.76	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.49	1.18	1.13	0.51	0.60	1.12	1.51	1.40	1.29	1.53	1.62
Accounts Receivable Turnover	10.35	8.21	5.22	3.79	6.51	0.00	0.00	17.03	10.51	12.19	15.32
Inventory Turnover	3.36	1.74	1.40	1.56	2.21	2.07	2.07	2.05	2.07	2.25	3.21
Fixed Asset Turnover	13.16	11.72	12.15	9.12	9.77	12.60	0.00	0.00	0.00	33.86	51.66
Accounts Payable Turnover	4.08	2.14	1.85	2.21	2.34	2.14	2.52	2.61	2.91	3.29	4.05
Days Sales Outstanding (DSO)	35.28	44.46	69.94	96.32	56.08	0.00	0.00	21.43	34.72	29.95	23.82
Days Inventory Outstanding (DIO)	108.51	209.97	260.40	233.29	165.35	175.94	176.68	177.75	176.42	162.53	113.87
Days Payable Outstanding (DPO)	89.40	170.60	197.52	165.03	156.19	170.51	145.12	139.68	125.41	110.82	90.06
Cash Conversion Cycle (CCC)	54.40	83.83	132.82	164.59	65.24	5.42	31.56	59.51	85.73	81.66	47.63
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2.81	5.26	7.72	8.95	4.56	1.63	-0.25	3.51	8.23	1.13	1.43
Invested Capital Turnover	6.46	4.43	3.34	2.54	4.67	14.94	85.88	41.44	12.28	17.85	77.66
Increase / (Decrease) in Invested Capital	0.87	2.46	2.46	1.23	-4.39	-2.93	-1.89	3.76	4.72	-7.10	0.30
Enterprise Value (EV)	156	160	124	238	166	238	280	227	105	80	361
Market Capitalization	157	160	125	283	189	257	297	255	125	107	405
Book Value per Share	$0.04	$0.05	$0.26	$1.12	$0.49	$0.34	$0.27	$0.46	$0.39	$0.38	$0.60
Tangible Book Value per Share	$0.03	$0.05	$0.25	$1.08	$0.47	$0.32	$0.25	$0.45	$0.38	$0.37	$0.60
Total Capital	6.77	11	11	54	27	20	16	32	29	28	46
Total Debt	2.77	5.54	0.60	0.51	0.00	0.00	0.02	0.00	0.00	0.00	0.00
Total Long-Term Debt	2.40	3.79	0.34	0.31	0.00	0.00	0.02	0.00	0.00	0.00	0.00
Net Debt	-1.19	-0.01	-1.06	-45	-23	-19	-17	-28	-20	-27	-45
Capital Expenditures (CapEx)	0.12	0.53	1.50	-4.79	1.32	0.74	0.12	0.41	0.33	0.15	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	1.32	3.16	5.48	3.90	-0.52	-0.36	-0.95	3.07	8.26	1.59	1.49
Debt-free Net Working Capital (DFNWC)	5.29	8.71	7.12	49	22	18	16	31	29	29	46
Net Working Capital (NWC)	4.92	6.96	6.87	49	22	18	16	31	29	29	46
Net Nonoperating Expense (NNE)	1.73	1.32	0.89	-0.09	10	10	6.03	8.18	3.50	1.02	-1.09
Net Nonoperating Obligations (NNO)	-1.19	-0.01	-2.25	-45	-23	-19	-17	-28	-20	-27	-45
Total Depreciation and Amortization (D&A)	0.26	0.33	0.42	0.72	0.84	2.37	1.51	1.63	1.88	1.03	0.81
Debt-free, Cash-free Net Working Capital to Revenue	8.65%	17.67%	25.30%	18.38%	-1.65%	-0.77%	-1.61%	4.56%	11.46%	1.90%	1.50%
Debt-free Net Working Capital to Revenue	34.54%	48.70%	32.88%	232.47%	70.01%	39.87%	26.57%	46.39%	39.83%	34.60%	46.34%
Net Working Capital to Revenue	32.12%	38.92%	31.70%	231.55%	70.01%	39.87%	26.57%	46.39%	39.83%	34.60%	46.34%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.05)	($0.03)	($0.08)	($0.26)	($0.61)	($0.56)	($0.33)	($0.40)	($0.24)	($0.07)	$0.11
Adjusted Weighted Average Basic Shares Outstanding	105.27M	109.53M	37.91M	54.84M	55.29M	59.79M	66.74M	67.19M	69.73M	74.99M	75.93M
Adjusted Diluted Earnings per Share	($0.05)	($0.03)	($0.08)	($0.26)	($0.61)	($0.56)	($0.33)	($0.40)	($0.24)	($0.07)	$0.11
Adjusted Weighted Average Diluted Shares Outstanding	105.27M	109.53M	37.91M	54.84M	55.29M	59.79M	66.74M	67.19M	69.73M	74.99M	78.13M
Adjusted Basic & Diluted Earnings per Share	($0.05)	($0.03)	($0.08)	($0.26)	($0.61)	($0.56)	($0.33)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	106.46M	107.63M	37.29M	44.60M	55.01M	57.06M	61.07M	68.31M	74.84M	75.31M	77.75M
Normalized Net Operating Profit after Tax (NOPAT)	-3.66	-1.45	-2.03	-11	-23	-22	-14	-19	-13	-3.92	7.46
Normalized NOPAT Margin	-23.91%	-8.09%	-9.39%	-54.07%	-73.58%	-47.33%	-23.45%	-28.10%	-18.10%	-4.69%	7.49%
Pre Tax Income Margin	-35.19%	-14.72%	-16.39%	-77.97%	-105.57%	-69.45%	-33.62%	-40.22%	-25.85%	-5.91%	8.89%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-32.93	-3.64	-4.49	-107.04	-420.72	0.00	-279.63	-492.24	0.00	0.00	0.00
NOPAT to Interest Expense	-23.05	-2.55	-3.15	-74.93	-293.93	0.00	-195.74	-344.57	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-33.71	-4.57	-6.82	-75.76	-437.44	0.00	-281.38	-499.67	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-23.83	-3.48	-5.47	-43.65	-310.65	0.00	-197.49	-352.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-1.76%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Niagen Bioscience's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.42%	18.23%	30.69%	21.46%	14.25%	0.95%	-1.79%	11.89%	31.21%	37.41%	37.59%
EBITDA Growth	68.95%	79.93%	78.73%	68.57%	73.28%	52.28%	66.30%	106.09%	381.55%	1,540.47%	1,064.47%
EBIT Growth	65.33%	72.84%	74.55%	63.74%	62.58%	88.37%	62.86%	88.95%	239.67%	4,332.74%	752.80%
NOPAT Growth	65.33%	72.84%	74.55%	63.74%	62.58%	83.38%	62.86%	88.95%	299.53%	4,332.74%	1,002.63%
Net Income Growth	88.88%	73.37%	75.43%	65.75%	2.64%	108.04%	74.13%	99.32%	295.83%	6,197.37%	1,129.07%
EPS Growth	92.31%	57.14%	72.73%	66.67%	0.00%	0.00%	66.67%	100.00%	300.00%	0.00%	700.00%
Operating Cash Flow Growth	36.81%	93.37%	138.79%	185.60%	110.59%	297.87%	-89.43%	-108.05%	782.58%	1,222.50%	2,572.20%
Free Cash Flow Firm Growth	-69.83%	23.37%	93.72%	136.48%	185.40%	220.90%	502.69%	-214.16%	-97.48%	-1.79%	110.72%
Invested Capital Growth	235.84%	134.64%	-11.57%	-82.90%	-93.24%	-86.26%	-71.58%	280.78%	268.41%	26.79%	-119.55%
Revenue Q/Q Growth	1.98%	23.05%	7.43%	-9.90%	-4.07%	8.73%	4.52%	2.65%	12.49%	13.86%	4.66%
EBITDA Q/Q Growth	56.08%	62.19%	-54.50%	-22.51%	62.66%	32.48%	-9.11%	133.43%	1,626.32%	245.48%	-26.95%
EBIT Q/Q Growth	52.01%	52.89%	-36.29%	-17.68%	50.48%	85.35%	-335.12%	64.98%	725.78%	343.88%	-32.89%
NOPAT Q/Q Growth	52.01%	52.89%	-36.29%	-17.68%	50.48%	79.08%	-204.58%	64.98%	993.97%	343.88%	-35.05%
Net Income Q/Q Growth	84.60%	-43.96%	-34.13%	-15.19%	56.23%	111.89%	-531.58%	96.95%	12,620.00%	282.27%	-29.47%
EPS Q/Q Growth	88.89%	-200.00%	0.00%	0.00%	66.67%	0.00%	0.00%	100.00%	0.00%	400.00%	-40.00%
Operating Cash Flow Q/Q Growth	2.40%	91.23%	951.22%	17.48%	-87.93%	63.89%	-54.55%	-189.49%	1,423.86%	145.58%	-8.16%
Free Cash Flow Firm Q/Q Growth	-41.51%	25.60%	87.10%	368.63%	231.24%	5.33%	-57.04%	-176.16%	107.32%	4,001.20%	-7.82%
Invested Capital Q/Q Growth	81.96%	3.94%	-40.76%	-84.74%	-28.09%	111.40%	22.55%	104.40%	-30.43%	-27.25%	-118.90%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	59.82%	57.23%	59.93%	60.80%	61.40%	61.04%	60.74%	60.22%	63.49%	62.48%	63.42%
EBITDA Margin	-15.33%	-4.71%	-6.77%	-9.21%	-3.59%	-2.23%	-2.32%	0.50%	7.69%	23.34%	16.30%
Operating Margin	-17.96%	-6.88%	-8.73%	-11.40%	-5.88%	-0.79%	-3.30%	-1.13%	6.26%	24.42%	15.66%
EBIT Margin	-17.96%	-6.88%	-8.73%	-11.40%	-5.88%	-0.79%	-3.30%	-1.13%	6.26%	24.42%	15.66%
Profit (Net Income) Margin	-5.77%	-6.75%	-8.43%	-10.78%	-4.92%	0.54%	-2.22%	-0.07%	7.34%	24.65%	16.61%
Tax Burden Percent	32.08%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	95.92%	96.79%
Interest Burden Percent	100.16%	98.20%	96.65%	94.60%	83.61%	-67.86%	67.31%	5.86%	117.23%	105.25%	109.62%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.21%
Return on Invested Capital (ROIC)	-168.39%	-59.10%	-90.93%	-253.40%	-81.23%	-14.15%	-61.36%	-37.71%	458.17%	1,896.07%	2,933.40%
ROIC Less NNEP Spread (ROIC-NNEP)	-173.41%	-57.42%	-88.52%	-250.74%	-80.45%	-15.33%	-61.43%	-38.32%	457.24%	1,895.88%	2,932.33%
Return on Net Nonoperating Assets (RNNOA)	141.85%	46.26%	71.46%	224.08%	66.38%	12.82%	54.68%	35.95%	-438.66%	-1,830.65%	-2,893.55%
Return on Equity (ROE)	-26.53%	-12.83%	-19.48%	-29.32%	-14.85%	-1.33%	-6.68%	-1.76%	19.51%	65.42%	39.85%
Cash Return on Invested Capital (CROIC)	-414.73%	-302.63%	-161.05%	-99.96%	60.84%	67.95%	13.94%	-206.90%	-78.93%	558.04%	0.00%
Operating Return on Assets (OROA)	-23.30%	-8.86%	-12.65%	-18.49%	-9.89%	-1.22%	-5.09%	-1.80%	10.44%	39.46%	24.95%
Return on Assets (ROA)	-7.49%	-8.70%	-12.23%	-17.49%	-8.27%	0.82%	-3.43%	-0.11%	12.24%	39.84%	26.48%
Return on Common Equity (ROCE)	-26.53%	-12.83%	-19.48%	-29.32%	-14.85%	-1.33%	-6.68%	-1.76%	19.51%	65.42%	39.85%
Return on Equity Simple (ROE_SIMPLE)	-97.26%	0.00%	-38.20%	-23.93%	-23.69%	0.00%	-12.19%	-4.40%	4.32%	0.00%	25.49%
Net Operating Profit after Tax (NOPAT)	-2.15	-1.01	-1.38	-1.62	-0.80	-0.17	-0.51	-0.18	1.60	7.11	4.62
NOPAT Margin	-12.57%	-4.81%	-6.11%	-7.98%	-4.12%	-0.79%	-2.31%	-0.79%	6.26%	24.42%	15.15%
Net Nonoperating Expense Percent (NNEP)	5.02%	-1.67%	-2.41%	-2.66%	-0.78%	1.18%	0.08%	0.60%	0.93%	0.19%	1.07%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-0.59%	-1.77%	-	-	15.43%	8.35%
Cost of Revenue to Revenue	40.18%	42.77%	40.07%	39.20%	38.60%	38.96%	39.26%	39.78%	36.51%	37.52%	36.58%
SG&A Expenses to Revenue	36.22%	28.55%	28.46%	35.91%	29.96%	25.60%	24.16%	24.91%	24.64%	3.62%	17.01%
R&D to Revenue	7.17%	6.09%	5.29%	6.72%	6.37%	5.47%	9.46%	5.79%	5.04%	4.52%	4.13%
Operating Expenses to Revenue	77.78%	64.11%	68.66%	72.19%	67.28%	61.83%	64.04%	61.34%	57.22%	38.06%	47.76%
Earnings before Interest and Taxes (EBIT)	-3.07	-1.44	-1.97	-2.32	-1.15	-0.17	-0.73	-0.26	1.60	7.11	4.77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.62	-0.99	-1.53	-1.87	-0.70	-0.47	-0.52	0.11	1.97	6.80	4.97
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.00	4.36	4.09	4.33	4.01	3.78	9.05	6.71	8.06	8.79	9.69
Price to Tangible Book Value (P/TBV)	4.14	4.47	4.18	4.43	4.09	3.84	9.20	6.81	8.16	8.86	9.75
Price to Revenue (P/Rev)	1.22	1.74	1.48	1.45	1.31	1.29	3.15	2.41	3.02	4.07	4.97
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	186.64	47.39	38.03
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.54%	2.11%	2.63%
Enterprise Value to Invested Capital (EV/IC)	8.94	12.72	18.74	122.70	154.72	70.82	169.20	62.95	124.18	251.43	0.00
Enterprise Value to Revenue (EV/Rev)	1.03	1.45	1.18	1.13	0.99	0.96	2.82	2.08	2.67	3.62	4.46
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	125.77	42.22	34.29
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	547.56	46.67	36.35
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	547.56	48.33	37.57
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	45.55	13.48	11.26	50.76	165.74	58.62	29.78	24.41
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	32.19	25.18	537.13	0.00	0.00	50.38	33.26
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.82	-0.81	-0.81	-0.89	-0.83	-0.84	-0.89	-0.94	-0.96	-0.97	-0.99
Leverage Ratio	1.88	1.85	1.98	2.08	2.05	1.91	1.89	1.85	1.78	1.65	1.61
Compound Leverage Factor	1.88	1.82	1.91	1.97	1.72	-1.30	1.27	0.11	2.09	1.74	1.76
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	99.99%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-1.75	0.03	-0.27	-0.28	-0.37	-0.28	3.46	2.63	5.27	9.84	11.68
Noncontrolling Interest Sharing Ratio	0.01%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.27	2.61	2.53	2.43	2.43	2.40	2.52	2.76	2.95	3.57	3.66
Quick Ratio	1.08	1.62	1.76	1.71	1.67	1.58	1.76	2.00	2.23	2.92	3.01
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-7.71	-5.73	-0.74	1.99	6.58	6.93	2.98	-2.27	0.17	6.81	6.28
Operating Cash Flow to CapEx	-7,192.31%	-190.70%	3,068.13%	32,800.00%	1,523.08%	3,090.48%	719.51%	-2,200.00%	8,524.39%	0.00%	24,634.38%
Free Cash Flow to Firm to Interest Expense	-1,541.30	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-748.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-758.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.30	1.29	1.45	1.62	1.68	1.53	1.54	1.60	1.67	1.62	1.59
Accounts Receivable Turnover	13.71	10.51	9.96	15.65	16.12	12.19	10.51	12.28	14.44	15.32	15.81
Inventory Turnover	1.92	2.07	2.32	2.37	2.37	2.25	2.66	2.86	3.05	3.21	3.42
Fixed Asset Turnover	23.43	0.00	0.00	0.00	32.80	33.86	35.47	39.42	45.71	51.66	59.06
Accounts Payable Turnover	2.73	2.91	3.37	3.25	3.66	3.29	3.85	3.70	4.39	4.05	4.37
Days Sales Outstanding (DSO)	26.62	34.72	36.65	23.33	22.65	29.95	34.73	29.72	25.28	23.82	23.09
Days Inventory Outstanding (DIO)	190.21	176.42	157.35	154.08	153.90	162.53	137.25	127.83	119.64	113.87	106.80
Days Payable Outstanding (DPO)	133.85	125.41	108.30	112.41	99.75	110.82	94.77	98.72	83.14	90.06	83.58
Cash Conversion Cycle (CCC)	82.99	85.73	85.70	65.00	76.79	81.66	77.21	58.83	61.77	47.63	46.32
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	7.92	8.23	4.88	0.74	0.54	1.13	1.39	2.83	1.97	1.43	-0.27
Invested Capital Turnover	13.39	12.28	14.89	31.77	19.72	17.85	26.56	47.85	73.16	77.66	193.59
Increase / (Decrease) in Invested Capital	5.56	4.72	-0.64	-3.61	-7.38	-7.10	-3.49	2.09	1.44	0.30	-1.66
Enterprise Value (EV)	71	105	91	91	83	80	235	178	245	361	481
Market Capitalization	84	125	115	118	110	107	262	206	277	405	536
Book Value per Share	$0.31	$0.39	$0.37	$0.36	$0.36	$0.38	$0.38	$0.41	$0.45	$0.60	$0.71
Tangible Book Value per Share	$0.30	$0.38	$0.37	$0.35	$0.36	$0.37	$0.38	$0.40	$0.45	$0.60	$0.71
Total Capital	21	29	28	27	27	28	29	31	34	46	55
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-13	-20	-23	-26	-27	-27	-28	-28	-32	-45	-56
Capital Expenditures (CapEx)	0.05	0.17	0.09	0.01	0.03	0.02	0.04	0.01	0.04	0.00	0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)	7.91	8.26	5.00	0.92	0.96	1.59	1.96	3.55	2.04	1.49	-0.24
Debt-free Net Working Capital (DFNWC)	21	29	28	27	28	29	30	31	34	46	55
Net Working Capital (NWC)	21	29	28	27	28	29	30	31	34	46	55
Net Nonoperating Expense (NNE)	-1.16	0.41	0.52	0.57	0.16	-0.28	-0.02	-0.16	-0.28	-0.07	-0.44
Net Nonoperating Obligations (NNO)	-13	-20	-23	-26	-27	-27	-28	-28	-32	-45	-56
Total Depreciation and Amortization (D&A)	0.45	0.46	0.44	0.44	0.45	-0.30	0.22	0.37	0.37	-0.31	0.20
Debt-free, Cash-free Net Working Capital to Revenue	11.50%	11.46%	6.47%	1.13%	1.16%	1.90%	2.36%	4.15%	2.22%	1.50%	-0.22%
Debt-free Net Working Capital to Revenue	30.77%	39.83%	36.38%	33.76%	33.27%	34.60%	35.50%	36.73%	37.56%	46.34%	51.31%
Net Working Capital to Revenue	30.77%	39.83%	36.38%	33.76%	33.27%	34.60%	35.50%	36.73%	37.56%	46.34%	51.31%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.01)	($0.03)	($0.03)	($0.03)	($0.01)	$0.00	($0.01)	$0.00	$0.02	$0.10	$0.07
Adjusted Weighted Average Basic Shares Outstanding	68.35M	69.73M	74.80M	74.97M	75.05M	74.99M	75.23M	75.56M	75.97M	75.93M	77.81M
Adjusted Diluted Earnings per Share	($0.01)	($0.03)	($0.03)	($0.03)	($0.01)	$0.00	($0.01)	$0.00	$0.02	$0.10	$0.06
Adjusted Weighted Average Diluted Shares Outstanding	68.35M	69.73M	74.80M	74.97M	75.05M	74.99M	75.23M	75.56M	77.77M	78.13M	83.23M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	74.47M	74.84M	74.97M	75.03M	75.12M	75.31M	75.54M	75.93M	76.38M	77.75M	78.77M
Normalized Net Operating Profit after Tax (NOPAT)	-2.15	-1.01	-1.38	-1.62	-0.80	-0.12	-0.51	-0.18	1.12	4.98	4.62
Normalized NOPAT Margin	-12.57%	-4.81%	-6.11%	-7.98%	-4.12%	-0.55%	-2.31%	-0.79%	4.38%	17.09%	15.15%
Pre Tax Income Margin	-17.99%	-6.75%	-8.43%	-10.78%	-4.92%	0.54%	-2.22%	-0.07%	7.34%	25.70%	17.16%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-613.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	-429.10	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-623.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-439.50	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Niagen Bioscience (NASDAQ: NAGE) quarterly statements over the last four years, focusing on revenue, profitability, cash flow, and liquidity. Items are grouped as positive, neutral, or negative, with positives shown first, then neutral, then negatives.

Strong late-2024 to early-2025 revenue and gross margin: Q1 2025 revenue was $30.481M with gross profit of $19.331M, implying a gross margin around 63%.
Profitability turning positive in Q1 2025: Net income attributable to common shareholders was $5.063M, with Basic EPS $0.07 and Diluted EPS $0.06.
Healthy liquidity position: Cash & equivalents reached $55.616M as of 2025-03-31, providing a solid liquidity cushion for near-term operations.
Positive operating cash flow in Q1 2025: Net cash from continuing operating activities was $7.883M, contributing to a positive net change in cash of $10.956M.
Low capital spending supports cash generation: Purchase of PP&E in Q1 2025 was only $32k, helping maintain strong free-cash-flow potential.

Equity financing strengthens the balance sheet: Total Common Equity increased to about $55.345M in Q1 2025, reflecting new equity financing that improves liquidity but may dilute existing holders.
Profitability has varied by quarter: While Q1 2025 was positive, prior quarters show mixed results with periods of losses, indicating some earnings volatility.
Balance sheet structure shows reliance on equity financing: A sizable common stock base alongside a substantial retained-earnings deficit suggests ongoing reliance on equity to fund operations.

Large accumulated deficits persist: Retained Earnings were about -$176.847M as of Q1 2025, signaling long-standing cumulative losses despite recent quarterly improvements.
Earnings volatility and past periods of negative net income: Several earlier quarters show negative net income and EPS, highlighting ongoing earnings risk despite improvements in recent quarters.

05/05/26 07:11 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Niagen Bioscience's Financials

When does Niagen Bioscience's fiscal year end?

According to the most recent income statement we have on file, Niagen Bioscience's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Niagen Bioscience's net income changed over the last 10 years?

Over the last 10 years, Niagen Bioscience's net income changed from -$5.39 million in 2014 to $8.55 million in 2024, a change of -258.7%. Find out what analysts predict for Niagen Bioscience in the coming months.

What is Niagen Bioscience's operating income?

Niagen Bioscience's total operating income in 2024 was $7.73 million, based on the following breakdown:

Total Gross Profit: $61.59 million
Total Operating Expenses: $53.86 million

How has Niagen Bioscience's revenue changed over the last 10 years?

Over the last 10 years, Niagen Bioscience's total revenue changed from $15.31 million in 2014 to $99.60 million in 2024, a change of 550.4%.

How much debt does Niagen Bioscience have?

Niagen Bioscience's total liabilities were at $22.18 million at the end of 2024, a 16.3% decrease from 2023, and a 195.1% increase since 2014.

How much cash does Niagen Bioscience have?

In the past 10 years, Niagen Bioscience's cash and equivalents has ranged from $0.00 in 2021 to $45.39 million in 2017, and is currently $44.66 million as of their latest financial filing in 2024.

How has Niagen Bioscience's book value per share changed over the last 10 years?

Over the last 10 years, Niagen Bioscience's book value per share changed from 0.04 in 2014 to 0.60 in 2024, a change of 1,513.6%.

Related Companies

Financial statements for NASDAQ:NAGE last updated on 6/22/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Niagen Bioscience (NAGE) Financials

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Niagen Bioscience's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Niagen Bioscience (NAGE) Financials

Annual Income Statements for Niagen Bioscience

Quarterly Income Statements for Niagen Bioscience

Annual Cash Flow Statements for Niagen Bioscience

Quarterly Cash Flow Statements for Niagen Bioscience

Annual Balance Sheets for Niagen Bioscience

Quarterly Balance Sheets for Niagen Bioscience

Annual Metrics And Ratios for Niagen Bioscience

Quarterly Metrics And Ratios for Niagen Bioscience

Financials Breakdown Chart

Key Financial Trends

Frequently Asked Questions About Niagen Bioscience's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools